Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicinal research reviews Ročník 38; číslo 2; s. 741 - 767
Hlavní autoři: Zhou, Fubo, Shang, Wenting, Yu, Xiaoling, Tian, Jie
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Wiley Subscription Services, Inc 01.03.2018
Témata:
Biomarkers, Tumor - metabolism
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Disease Progression
Glypicans - blood
Glypicans - chemistry
Glypicans - metabolism
glypican‐3
hepatocellular carcinoma
Humans
Liver cancer
Liver Neoplasms - blood
Liver Neoplasms - diagnosis
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Medical imaging
Molecular Targeted Therapy
glypican-3
hepatocellular carcinoma
ISSN:0198-6325, 1098-1128, 1098-1128
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3‐targeted magnetic resonance imaging, positron emission tomography, and near‐infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti‐GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
AbstractList Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3‐targeted magnetic resonance imaging, positron emission tomography, and near‐infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti‐GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3-targeted magnetic resonance imaging, positron emission tomography, and near-infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti-GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3-targeted magnetic resonance imaging, positron emission tomography, and near-infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti-GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
Author Zhou, Fubo
Yu, Xiaoling
Shang, Wenting
Tian, Jie
Author_xml – sequence: 1
  givenname: Fubo
  surname: Zhou
  fullname: Zhou, Fubo
  organization: Chinese PLA General Hospital
– sequence: 2
  givenname: Wenting
  surname: Shang
  fullname: Shang, Wenting
  organization: Chinese Academy of Sciences
– sequence: 3
  givenname: Xiaoling
  orcidid: 0000-0003-1349-2334
  surname: Yu
  fullname: Yu, Xiaoling
  email: dyuxl301@aliyun.com
  organization: Chinese PLA General Hospital
– sequence: 4
  givenname: Jie
  surname: Tian
  fullname: Tian, Jie
  email: jie.tian@ia.ac.cn
  organization: Chinese Academy of Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28621802$$D View this record in MEDLINE/PubMed
BookMark eNp9kbtOAzEQRS0EgvAo-AFkiQaKgB-7G5su4i2BaFLQrWadWTBs7GDvCqXjE_hGvgSHBAokqGaKc0dHdzbJqvMOCdnl7IgzJo4nOD4SPMvzFdLjTKs-50Ktkh7jaS-kyDfIZoxPjHGec7lONoQqBFdM9Mj9ZTObWgPu4-1dntAhnQY_sdG6B1pZP4HwjIHWPtBHnELrDTZN10CgBoKxLgF0bOHB-WgjBTembUBoJ-jabbJWQxNxZzm3yOjifHR61b-5u7w-Hd70TcZ13h_IWo5ZAVJozFlWqUqx3DClAZiowUgFlZCgsJaISiR9KQYaVa11zVHILXKwOJu8XzqMbZns55bg0Hex5Jqzgc6KXCV0_xf65LvgklwpUjVyUGQFS9Tekuqq1Gs5DTa1MCu_K0vA4QIwwccYsP5BOCvn7yjnsa93JPb4F2tsC631rg1gm_8Sr7bB2d-ny9vzs0XiE4r8mus
CitedBy_id crossref_primary_10_2174_0929867327666200320153837
crossref_primary_10_1158_2326_6066_CIR_23_1102
crossref_primary_10_3350_cmh_2025_0287
crossref_primary_10_1080_2162402X_2021_2010894
crossref_primary_10_1186_s13046_019_1218_8
crossref_primary_10_3389_fphys_2023_1138239
crossref_primary_10_1080_15513815_2020_1865490
crossref_primary_10_3389_fonc_2022_962272
crossref_primary_10_1016_j_imbio_2019_09_009
crossref_primary_10_1016_j_jss_2022_09_011
crossref_primary_10_4254_wjh_v17_i1_102273
crossref_primary_10_2174_0113816128298875240321073907
crossref_primary_10_3390_cancers13112772
crossref_primary_10_3390_cancers13153645
crossref_primary_10_3390_biomedicines11071852
crossref_primary_10_4251_wjgo_v12_i10_1195
crossref_primary_10_3390_cells14100726
crossref_primary_10_1007_s13193_023_01858_x
crossref_primary_10_1016_j_hbpd_2018_05_005
crossref_primary_10_1016_j_crad_2023_06_009
crossref_primary_10_1038_s41598_019_39440_7
crossref_primary_10_1016_j_gpb_2018_07_003
crossref_primary_10_1038_s41423_025_01308_4
crossref_primary_10_1016_j_jbo_2021_100391
crossref_primary_10_3389_fimmu_2021_765101
crossref_primary_10_1053_j_semnuclmed_2024_02_003
crossref_primary_10_1007_s10142_024_01406_y
crossref_primary_10_1016_j_electacta_2022_140808
crossref_primary_10_2147_JHC_S327339
crossref_primary_10_3389_fonc_2020_605057
crossref_primary_10_1016_j_bbcan_2023_189016
crossref_primary_10_1093_jjco_hyad147
crossref_primary_10_1016_j_prp_2024_155216
crossref_primary_10_3390_biom11020136
crossref_primary_10_1186_s12964_021_00796_x
crossref_primary_10_1155_2021_6756763
crossref_primary_10_3233_CH_231912
crossref_primary_10_3389_fonc_2023_1209814
crossref_primary_10_1007_s00604_023_06098_y
crossref_primary_10_1016_j_ymthe_2021_01_021
crossref_primary_10_1038_s42003_021_02337_1
crossref_primary_10_1186_s13046_021_01968_w
crossref_primary_10_1007_s10800_021_01534_4
crossref_primary_10_3389_fonc_2023_1142916
crossref_primary_10_4251_wjgo_v17_i5_106278
crossref_primary_10_3390_cancers14081902
crossref_primary_10_3389_fgene_2023_1106665
crossref_primary_10_1007_s11684_024_1071_9
crossref_primary_10_1097_PAI_0000000000001080
crossref_primary_10_1186_s12967_025_06106_0
crossref_primary_10_1021_acs_jmedchem_5c01019
crossref_primary_10_1186_s12885_025_14025_y
crossref_primary_10_1016_j_biopha_2022_113919
crossref_primary_10_1016_j_clinimag_2023_04_001
crossref_primary_10_1016_j_colsurfb_2020_111358
crossref_primary_10_1016_j_bioelechem_2020_107696
crossref_primary_10_1016_j_tranon_2021_101097
crossref_primary_10_1080_13813455_2023_2206982
crossref_primary_10_1016_j_omtn_2018_09_013
crossref_primary_10_1038_s41598_023_48366_0
crossref_primary_10_1093_ajcp_aqz086
crossref_primary_10_1055_s_0041_1725063
crossref_primary_10_1055_s_0041_1725067
crossref_primary_10_1002_wnan_1749
crossref_primary_10_1186_s12859_022_04670_6
crossref_primary_10_1016_j_prp_2025_156089
crossref_primary_10_3389_fonc_2022_968202
crossref_primary_10_1007_s11101_025_10165_y
crossref_primary_10_3390_cancers16101831
crossref_primary_10_3390_ijms26125838
crossref_primary_10_3762_bjnano_16_10
crossref_primary_10_1002_adfm_202315721
crossref_primary_10_3390_cancers15061640
crossref_primary_10_1016_j_bioorg_2020_104536
crossref_primary_10_3389_fonc_2023_1123141
crossref_primary_10_1097_MD_0000000000025234
crossref_primary_10_3390_molecules29184405
crossref_primary_10_1007_s10528_023_10436_3
crossref_primary_10_1016_j_prp_2024_155163
crossref_primary_10_1016_j_ejrad_2021_109732
crossref_primary_10_3389_fonc_2021_744331
crossref_primary_10_3390_ijms22116139
crossref_primary_10_1002_jcb_28952
crossref_primary_10_1007_s00210_024_03443_7
crossref_primary_10_1002_smll_202406374
crossref_primary_10_3390_cancers12061668
crossref_primary_10_5306_wjco_v12_i5_290
crossref_primary_10_3390_ijtm3010005
crossref_primary_10_1038_s41419_020_03048_x
crossref_primary_10_3389_fonc_2020_00397
crossref_primary_10_1016_j_bioelechem_2024_108709
crossref_primary_10_1038_s41417_020_00259_4
crossref_primary_10_1007_s12079_021_00645_z
crossref_primary_10_1155_2021_3554219
crossref_primary_10_3390_gidisord2040042
crossref_primary_10_1177_1758835920910347
crossref_primary_10_3390_cancers14051298
crossref_primary_10_3389_fonc_2023_1140256
crossref_primary_10_1016_j_yasu_2025_04_008
crossref_primary_10_1155_2022_1739995
crossref_primary_10_1002_ijc_32970
crossref_primary_10_2147_OTT_S437536
crossref_primary_10_4254_wjh_v17_i2_101201
crossref_primary_10_1016_j_actbio_2022_12_062
crossref_primary_10_3389_fonc_2021_679336
crossref_primary_10_3350_cmh_2024_0948
crossref_primary_10_1155_2022_9117205
crossref_primary_10_3892_ol_2021_12490
crossref_primary_10_1080_1061186X_2025_2461104
crossref_primary_10_4251_wjgo_v15_i3_405
crossref_primary_10_1080_15384101_2020_1731945
crossref_primary_10_1016_j_ajg_2024_12_002
crossref_primary_10_2174_1874467214666210811150255
crossref_primary_10_3390_ijms25052631
crossref_primary_10_1002_14651858_CD015851
crossref_primary_10_3892_ijmm_2024_5383
crossref_primary_10_1007_s00216_022_04201_5
crossref_primary_10_1186_s12967_021_02791_9
crossref_primary_10_1016_j_yexcr_2024_114391
crossref_primary_10_1097_DAD_0000000000002854
crossref_primary_10_1016_j_apsb_2025_05_030
crossref_primary_10_2147_JHC_S376210
crossref_primary_10_1080_15384101_2022_2057633
crossref_primary_10_1186_s12876_022_02152_w
crossref_primary_10_1016_j_drudis_2023_103660
crossref_primary_10_3390_bios12050342
crossref_primary_10_3390_diagnostics14141519
crossref_primary_10_3390_ijms21186588
crossref_primary_10_1039_D0BM00943A
crossref_primary_10_1080_14728222_2025_2471581
crossref_primary_10_1016_j_nantod_2023_101940
crossref_primary_10_3748_wjg_v29_i6_1054
crossref_primary_10_1021_jacs_3c05052
crossref_primary_10_1155_2019_2560650
crossref_primary_10_1016_j_molimm_2021_01_010
crossref_primary_10_1021_acs_jmedchem_5c02081
crossref_primary_10_1186_s12944_024_02429_x
crossref_primary_10_32604_or_2023_044473
crossref_primary_10_1007_s11307_019_01356_z
crossref_primary_10_1016_j_acra_2020_05_015
crossref_primary_10_1134_S106816202102028X
crossref_primary_10_1016_j_bcp_2020_114084
crossref_primary_10_3389_fmolb_2021_738219
crossref_primary_10_1007_s00432_020_03378_5
crossref_primary_10_1097_CM9_0000000000002641
crossref_primary_10_1111_jcmm_18468
crossref_primary_10_1002_btm2_10482
crossref_primary_10_3748_wjg_v29_i28_4384
crossref_primary_10_1002_jbt_70091
crossref_primary_10_1007_s10637_025_01530_x
crossref_primary_10_1016_j_ejmech_2023_116047
crossref_primary_10_1038_s41598_025_09918_8
crossref_primary_10_1186_s40001_024_02073_2
crossref_primary_10_1016_j_bioorg_2020_103995
crossref_primary_10_1109_JSEN_2022_3224554
crossref_primary_10_3389_fonc_2021_667428
crossref_primary_10_2147_IJN_S307691
crossref_primary_10_3390_cancers13102438
crossref_primary_10_3390_ijms241310922
crossref_primary_10_1002_smsc_202400447
crossref_primary_10_1186_s12885_025_14224_7
crossref_primary_10_3390_cancers15194677
crossref_primary_10_3390_jcm9051541
crossref_primary_10_1007_s00262_025_04122_z
crossref_primary_10_1111_jcmm_17235
crossref_primary_10_1038_s41598_020_79524_3
crossref_primary_10_1186_s13100_025_00366_9
crossref_primary_10_4251_wjgo_v15_i4_644
crossref_primary_10_1111_bph_15046
crossref_primary_10_1002_anbr_202200014
crossref_primary_10_1155_2019_5376165
crossref_primary_10_1007_s10637_020_01033_x
crossref_primary_10_1186_s12967_024_05724_4
crossref_primary_10_3389_fonc_2022_855952
crossref_primary_10_1111_liv_14771
crossref_primary_10_3350_cmh_2025_0216
crossref_primary_10_1038_s41598_019_43376_3
crossref_primary_10_31083_j_fbl2907268
crossref_primary_10_3390_ijms25052557
crossref_primary_10_1016_j_compbiolchem_2024_108166
crossref_primary_10_3389_fimmu_2024_1489649
crossref_primary_10_1186_s11658_023_00493_2
crossref_primary_10_3390_cancers14030504
crossref_primary_10_1016_j_hbpd_2023_12_004
crossref_primary_10_1016_j_antiviral_2020_104748
crossref_primary_10_1016_j_preteyeres_2022_101118
crossref_primary_10_1093_bib_bbae686
crossref_primary_10_3389_fimmu_2023_1145788
crossref_primary_10_1002_cam4_3434
crossref_primary_10_3389_fonc_2022_822449
crossref_primary_10_3389_fimmu_2022_857308
crossref_primary_10_1016_j_pep_2022_106094
crossref_primary_10_1016_j_bios_2023_115081
crossref_primary_10_1039_D1BM02021H
crossref_primary_10_4103_ejcrp_eJCRP_D_22_00037
crossref_primary_10_3389_fgene_2024_1491577
crossref_primary_10_1186_s12885_021_08704_9
crossref_primary_10_1007_s00216_025_05791_6
crossref_primary_10_1007_s11307_019_01437_z
crossref_primary_10_1177_13860291251376273
crossref_primary_10_1016_j_chmed_2024_04_002
crossref_primary_10_3390_ijms231810279
crossref_primary_10_1111_cas_15521
crossref_primary_10_1016_j_hbpd_2019_12_001
crossref_primary_10_3389_fonc_2023_1026245
crossref_primary_10_1007_s00604_024_06704_7
crossref_primary_10_1016_j_livres_2020_10_001
crossref_primary_10_1038_s41392_021_00799_7
crossref_primary_10_5306_wjco_v12_i7_507
crossref_primary_10_2147_JHC_S297601
crossref_primary_10_1007_s00604_020_04284_w
crossref_primary_10_1080_13543784_2022_2079491
crossref_primary_10_1007_s00726_024_03438_x
crossref_primary_10_1371_journal_pone_0307048
crossref_primary_10_1177_17562848241293019
crossref_primary_10_3390_biomedicines8120576
crossref_primary_10_1016_j_actbio_2018_05_030
crossref_primary_10_1038_s41419_025_07941_1
crossref_primary_10_1186_s12951_022_01378_w
crossref_primary_10_1002_cam4_5883
crossref_primary_10_1016_j_apsb_2025_02_037
crossref_primary_10_1016_j_bcp_2025_117229
crossref_primary_10_1016_j_iliver_2023_01_003
crossref_primary_10_1080_07853890_2023_2189295
crossref_primary_10_1186_s12920_021_00883_5
crossref_primary_10_3389_fchem_2021_700956
crossref_primary_10_1002_iid3_70171
crossref_primary_10_12998_wjcc_v10_i11_3321
crossref_primary_10_1007_s00259_022_05884_9
crossref_primary_10_3390_ijms26051936
crossref_primary_10_1186_s12967_025_06070_9
Cites_doi 10.1016/j.bbrc.2015.11.084
10.1002/ijc.29518
10.2217/14796694.4.6.803
10.1002/hep.25891
10.1016/j.febslet.2012.02.017
10.1016/j.bbrc.2008.11.033
10.1074/jbc.272.12.7574
10.1016/j.acthis.2011.10.003
10.1002/hep.23848
10.1042/bj20030171
10.1002/hep.26996
10.1093/glycob/11.3.19R
10.1136/gutjnl-2011-301862
10.1371/journal.pone.0087120
10.1016/S1016-8478(23)12884-6
10.18632/oncotarget.10592
10.1002/hep.22202
10.3892/ijo.2015.2827
10.7150/jca.14645
10.1111/j.1478-3231.2008.01968.x
10.3892/ijo.2013.1793
10.1016/S1499-3872(11)60048-9
10.1016/S1499-3872(13)60028-4
10.1158/1078-0432.CCR-12-2616
10.1002/smll.201501985
10.1515/cclm-2015-0773
10.1080/2162402X.2015.1062209
10.1002/ajmg.c.31360
10.18632/oncotarget.12945
10.1016/j.surg.2013.02.014
10.4161/cbt.8.10.8149
10.18632/oncotarget.12760
10.2217/nnm.14.194
10.1016/j.devcel.2008.03.006
10.1111/j.1440-1746.2009.05988.x
10.1007/s13277-012-0593-y
10.1111/j.1478-3231.2011.02646.x
10.1002/gcc.20838
10.1002/ijc.24941
10.1210/jc.2012-4297
10.1097/PAI.0000000000000042
10.1593/neo.11664
10.1016/j.biocel.2014.08.021
10.1042/BJ20070511
10.1111/j.1349-7006.2009.01206.x
10.1007/s12032-014-0359-z
10.2967/jnumed.113.132118
10.1111/cas.12368
10.4161/hv.24179
10.1021/acs.bioconjchem.6b00030
10.1016/j.ajme.2014.01.002
10.2967/jnumed.114.145102
10.1158/1078-0432.CCR-11-3044
10.1002/hep.21531
10.1016/j.anndiagpath.2013.08.001
10.1073/pnas.0911427107
10.1006/dbio.2000.9831
10.1016/j.cell.2004.06.006
10.5009/gnl.2014.8.2.177
10.1083/jcb.201008087
10.1172/JCI200113712
10.1002/ijc.25549
10.1007/s13277-014-1776-5
10.1016/j.humpath.2006.05.016
10.1186/gb-2008-9-5-224
10.1016/S0006-291X(03)00908-2
10.1158/1055-9965.EPI-13-0179
10.1021/acs.molpharmaceut.5b00132
10.1038/nature14259
10.1038/ncomms14351
10.4161/cc.8.4.7657
10.1371/journal.pone.0151501
10.1002/jcla.20443
10.1002/hep.510250413
10.1158/1078-0432.CCR-04-1177
10.1016/S1499-3872(15)60349-6
10.3892/ijo.2014.2737
10.1309/HCQWPWD50XHD2DW6
10.1111/j.1478-3231.2010.02359.x
10.1016/j.jhep.2016.04.004
10.3892/mmr.2015.3239
10.1073/pnas.0912203107
10.1038/bjc.2013.390
10.1016/j.arcmed.2014.11.002
10.1007/s11033-011-0745-y
10.1158/1078-0432.CCR-05-2267
10.1016/j.nano.2015.12.381
10.1038/ng0396-241
10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U
10.1038/nrc1891
10.1002/hep.21825
10.1002/jcla.21733
10.1016/j.anndiagpath.2010.10.004
10.1309/09B452V7R76K7D6K
10.1016/j.ceb.2003.10.006
10.1016/j.bbrc.2012.02.069
10.1093/hmg/9.9.1321
10.1038/ncomms7536
10.3233/CBM-2012-0261
10.1016/j.biomaterials.2014.04.089
10.1158/0008-5472.CAN-04-4244
10.3748/wjg.v16.i28.3521
10.1038/nrc1256
10.1002/ijc.10856
10.1074/jbc.M507004200
10.1158/0008-5472.CAN-06-1650
10.1016/j.ydbio.2005.03.003
10.1002/hep.24289
10.1073/pnas.1217868110
10.1016/S0140-6736(11)61347-0
10.4161/mabs.20933
10.1007/s00262-012-1366-6
10.1177/1533034615605248
10.3389/fonc.2014.00015
10.1111/jdi.12071
10.1007/s00535-013-0793-2
10.1261/rna.036483.112
10.1002/hep.25994
10.1016/j.acthis.2008.11.025
10.1053/j.gastro.2015.05.055
10.1002/ijc.29210
10.1016/j.jhep.2008.11.014
10.3892/mmr.2014.2600
10.1016/j.ydbio.2009.08.029
10.1111/hepr.12121
10.7314/APJCP.2013.14.12.7345
10.1371/journal.pone.0137664
10.18632/oncotarget.9892
10.1309/AJCPK1ZC9WNHCCMU
10.1053/j.gastro.2006.09.014
10.1158/0008-5472.CAN-03-2191
10.1158/1078-0432.CCR-14-1170
10.1016/j.clinbiochem.2013.12.007
10.1038/nrc2853
10.5858/132.11.1723
10.1111/j.1872-034X.2010.00624.x
10.1016/j.jhep.2013.07.001
10.1158/0008-5472.CAN-05-0616
10.1016/S0016-5085(03)00689-9
10.1074/jbc.M410090200
10.1016/j.cca.2013.04.026
10.1111/j.1478-3231.2005.01100.x
10.1080/2162402X.2015.1129483
10.1111/apm.12491
10.3748/wjg.v22.i1.275
10.1038/bjc.2016.183
10.1158/0008-5472.CAN-08-1973
10.1093/nar/gkr843
10.1002/jcb.24404
10.1038/nrendo.2012.133
10.3892/mco.2015.486
10.4161/cbt.8.24.9985
10.1007/s11033-013-2829-3
10.1002/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I
10.3748/wjg.v18.i19.2408
10.1136/gut.48.4.558
10.1083/jcb.200302152
10.1172/JCI27236
ContentType Journal Article
Copyright 2017 Wiley Periodicals, Inc.
Copyright © 2018 Wiley Periodicals, Inc.
Copyright_xml – notice: 2017 Wiley Periodicals, Inc.
– notice: Copyright © 2018 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
DOI 10.1002/med.21455
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
ProQuest Health & Medical Complete (Alumni)

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1098-1128
EndPage 767
ExternalDocumentID 28621802
10_1002_med_21455
MED21455
Genre reviewArticle
Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: National Science and Technology Major Project of China
  funderid: 2017ZX10203204‐008
– fundername: National Natural Science Foundation of China
  funderid: 81471683; 81671710
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADXHL
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
GWYGA
H.X
HBH
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
UB1
V8K
W8V
W99
WBFHL
WBKPD
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WXI
WXSBR
WYISQ
XG1
XV2
ZGI
ZZTAW
~IA
~WT
AAYXX
CITATION
O8X
AAHHS
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
CGR
CUY
CVF
ECM
EIF
NPM
PKN
RWI
WRC
WUP
WWP
YCJ
K9.
7X8
ID FETCH-LOGICAL-c4195-73f3d06a329e504b8b805c089aa02fac38ab23a8ef3ee825133279e8f99f1e23
IEDL.DBID DRFUL
ISICitedReferencesCount 292
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000425027400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0198-6325
1098-1128
IngestDate Thu Sep 04 18:51:03 EDT 2025
Sat Nov 29 14:37:04 EST 2025
Wed Feb 19 02:42:20 EST 2025
Tue Nov 18 22:30:51 EST 2025
Sat Nov 29 03:20:11 EST 2025
Sun Sep 21 06:24:38 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords glypican-3
hepatocellular carcinoma
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4195-73f3d06a329e504b8b805c089aa02fac38ab23a8ef3ee825133279e8f99f1e23
Notes These authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-1349-2334
PMID 28621802
PQID 2001376460
PQPubID 1016383
PageCount 27
ParticipantIDs proquest_miscellaneous_1910794658
proquest_journals_2001376460
pubmed_primary_28621802
crossref_primary_10_1002_med_21455
crossref_citationtrail_10_1002_med_21455
wiley_primary_10_1002_med_21455_MED21455
PublicationCentury 2000
PublicationDate March 2018
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: March 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Medicinal research reviews
PublicationTitleAlternate Med Res Rev
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 10
2010; 16
2013; 4
2010; 107
2015; 149
2000; 89
1997; 272
2013; 62
2006; 37
2004; 4
2011; 53
2005; 65
2012; 19
2011; 192
2001; 48
2012; 18
2008; 32
2011; 58
2013; 9
2014; 20
2014; 127
2013; 59
2010; 25
2011; 128
2015; 137
2006; 21
2013; 57
2015; 136
1997; 57
2010; 112
2012; 419
2008; 23
2013; 114
2013; 110
2012; 379
2012; 138
2007; 67
2014; 10
2003; 163
1996; 66
2011; 1
2012; 586
2013; 109
1997; 25
2014; 49
2008; 129
2014; 47
2012; 39
2013; 163C
2006; 116
2016; 15
2012; 32
2014; 45
2009; 335
2014; 44
2010; 40
2016; 12
1996; 12
2016; 11
2016; 4
2016; 5
2016; 6
2016; 7
2000; 225
2008; 47
2009; 100
2015; 519
2014; 35
2008; 410
2012; 114
2003; 103
2016; 27
2008; 132
2010; 52
2016; 22
2012; 40
2012; 61
2017; 8
2004; 64
2013; 22
2000; 9
2015; 32
2008; 9
2003; 15
2011; 11
2006; 131
2011; 10
2011; 13
2016; 469
2011; 15
2008; 4
2001; 108
2012; 56
2014; 61
2014; 60
2005; 25
2013; 19
2015; 46
2014; 4
2013; 14
2013; 17
2013; 98
2013; 13
2009; 50
2013; 12
2008; 68
2016; 115
2013; 154
2011; 25
2001; 11
2011; 28
2014; 9
2003; 125
2014; 8
2014; 50
2014; 55
2006; 125
2015; 12
2015; 14
2015; 6
2015; 19
2015; 3
2006; 12
2013; 40
2010; 126
2013; 423
2013; 42
2015; 11
2015; 10
2016; 54
2008; 14
2011; 31
2016; 124
2006; 6
2006; 2
2009; 378
2009; 29
2003; 373
2004; 10
2015; 23
2005; 280
2014; 105
2005; 282
2003; 306
2015; 29
2017; 17
2013; 34
2011; 50
2016; 65
2009; 8
2017; 18
2012; 7
2012; 4
2004; 117
2007; 45
2007; 46
2012; 8
e_1_2_12_6_1
e_1_2_12_130_1
e_1_2_12_172_1
e_1_2_12_2_1
Abdelgawad IA MG (e_1_2_12_107_1) 2013; 14
e_1_2_12_157_1
Li B (e_1_2_12_11_1) 2013; 13
e_1_2_12_134_1
e_1_2_12_176_1
e_1_2_12_108_1
e_1_2_12_43_1
e_1_2_12_85_1
Qin Z (e_1_2_12_120_1) 2017; 17
e_1_2_12_24_1
Saber MA (e_1_2_12_97_1) 2017; 18
e_1_2_12_47_1
Sham JG (e_1_2_12_115_1) 2014; 55
e_1_2_12_62_1
e_1_2_12_81_1
e_1_2_12_161_1
Gao W (e_1_2_12_25_1) 2011; 1
Baumhoer D (e_1_2_12_26_1) 2008; 129
Hsu HC (e_1_2_12_40_1) 1997; 57
Wong KF (e_1_2_12_78_1) 2016; 7
e_1_2_12_100_1
e_1_2_12_123_1
e_1_2_12_146_1
e_1_2_12_169_1
e_1_2_12_28_1
e_1_2_12_104_1
Wang L (e_1_2_12_121_1) 2016; 7
e_1_2_12_142_1
e_1_2_12_165_1
e_1_2_12_31_1
Lee C‐C (e_1_2_12_67_1) 2006; 2
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_96_1
Liu JW (e_1_2_12_111_1) 2015; 19
Wang YL (e_1_2_12_127_1) 2011; 11
e_1_2_12_35_1
Yu MC (e_1_2_12_128_1) 2012; 19
e_1_2_12_58_1
e_1_2_12_12_1
e_1_2_12_73_1
e_1_2_12_50_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_171_1
e_1_2_12_18_1
Filmus J (e_1_2_12_15_1) 2008; 9
e_1_2_12_110_1
e_1_2_12_137_1
Capurro MI (e_1_2_12_23_1) 2005; 280
e_1_2_12_114_1
e_1_2_12_133_1
e_1_2_12_156_1
Wang HL (e_1_2_12_164_1) 2008; 132
e_1_2_12_175_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_48_1
Wang S (e_1_2_12_34_1) 2016; 7
e_1_2_12_82_1
e_1_2_12_160_1
Jalvy‐Delvaille S (e_1_2_12_89_1) 2012; 40
e_1_2_12_141_1
Sham JG (e_1_2_12_116_1) 2014; 55
e_1_2_12_122_1
e_1_2_12_168_1
e_1_2_12_103_1
e_1_2_12_145_1
e_1_2_12_119_1
e_1_2_12_55_1
e_1_2_12_74_1
Williamson D (e_1_2_12_32_1) 2007; 67
e_1_2_12_59_1
Capurro M (e_1_2_12_56_1) 2014; 127
e_1_2_12_13_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_93_1
e_1_2_12_4_1
e_1_2_12_174_1
Guo L (e_1_2_12_33_1) 2016; 6
e_1_2_12_151_1
e_1_2_12_19_1
e_1_2_12_170_1
e_1_2_12_38_1
e_1_2_12_136_1
e_1_2_12_159_1
Nakatsura T (e_1_2_12_138_1) 2004; 10
Li YW (e_1_2_12_117_1) 2012; 7
e_1_2_12_132_1
e_1_2_12_178_1
Kwack MH (e_1_2_12_66_1) 2006; 21
e_1_2_12_113_1
e_1_2_12_155_1
Ruan J (e_1_2_12_153_1) 2011; 28
e_1_2_12_41_1
e_1_2_12_87_1
e_1_2_12_129_1
e_1_2_12_22_1
e_1_2_12_64_1
e_1_2_12_45_1
Li SQ (e_1_2_12_149_1) 2014; 61
e_1_2_12_68_1
Pan C (e_1_2_12_167_1) 2015; 32
e_1_2_12_83_1
Komori H (e_1_2_12_139_1) 2006; 12
e_1_2_12_60_1
e_1_2_12_163_1
Herreros‐Villanueva M (e_1_2_12_16_1) 2016; 4
Wang YL (e_1_2_12_126_1) 2012; 18
e_1_2_12_49_1
e_1_2_12_148_1
Hippo Y (e_1_2_12_36_1) 2004; 64
Akutsu N (e_1_2_12_57_1) 2010; 16
e_1_2_12_102_1
e_1_2_12_125_1
e_1_2_12_144_1
e_1_2_12_52_1
e_1_2_12_98_1
e_1_2_12_75_1
Motomura Y (e_1_2_12_140_1) 2008; 32
e_1_2_12_37_1
Cat B (e_1_2_12_44_1) 2003; 163
e_1_2_12_79_1
e_1_2_12_14_1
Diamandis EP (e_1_2_12_17_1) 2016; 54
Maurel M (e_1_2_12_90_1) 2013; 19
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_94_1
e_1_2_12_71_1
e_1_2_12_150_1
Bologna‐Molina R (e_1_2_12_20_1) 2015; 23
e_1_2_12_5_1
e_1_2_12_112_1
e_1_2_12_135_1
Wang C (e_1_2_12_152_1) 2017; 8
e_1_2_12_158_1
e_1_2_12_39_1
e_1_2_12_131_1
e_1_2_12_154_1
e_1_2_12_177_1
Wang W (e_1_2_12_106_1) 2011; 11
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_88_1
e_1_2_12_109_1
Qiao SS (e_1_2_12_173_1) 2011; 58
e_1_2_12_46_1
e_1_2_12_69_1
e_1_2_12_80_1
e_1_2_12_84_1
e_1_2_12_162_1
e_1_2_12_27_1
Mitchell F (e_1_2_12_29_1) 2012; 8
e_1_2_12_101_1
e_1_2_12_147_1
Truong Q (e_1_2_12_21_1) 2016; 7
e_1_2_12_105_1
e_1_2_12_143_1
Iglesias BV (e_1_2_12_9_1) 2008; 23
Kaposi‐Novak P (e_1_2_12_61_1) 2006; 116
e_1_2_12_124_1
e_1_2_12_166_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_99_1
Park JO (e_1_2_12_118_1) 2011; 10
e_1_2_12_91_1
e_1_2_12_72_1
e_1_2_12_95_1
References_xml – volume: 57
  start-page: 5179
  issue: 22
  year: 1997
  end-page: 5184
  article-title: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution
  publication-title: Cancer Res
– volume: 10
  start-page: e0137664
  issue: 9
  year: 2015
  article-title: Human monoclonal antibody targeting the heparan sulfate chains of glypican‐3 inhibits HGF‐mediated migration and motility of hepatocellular carcinoma cells
  publication-title: PloS One
– volume: 25
  start-page: 862
  issue: 4
  year: 1997
  end-page: 866
  article-title: Expression of hepatocyte growth factor and its receptor c‐met proto‐oncogene in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 105
  start-page: 455
  issue: 4
  year: 2014
  end-page: 462
  article-title: Japanese phase I study of GC33, a humanized antibody against glypican‐3 for advanced hepatocellular carcinoma
  publication-title: Cancer Sci
– volume: 32
  start-page: 359
  issue: 1
  year: 2015
  article-title: Reevaluation of glypican‐3 as a prognostic marker in HCC using X‐tile software
  publication-title: Med Oncol
– volume: 154
  start-page: 536
  issue: 3
  year: 2013
  end-page: 544
  article-title: Glypican‐3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection
  publication-title: Surgery
– volume: 50
  start-page: 746
  issue: 4
  year: 2009
  end-page: 754
  article-title: The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
  publication-title: J Hepatol
– volume: 9
  start-page: 224.1
  issue: 5
  year: 2008
  end-page: 224.6
  article-title: Glypicans
  publication-title: Genome Biol
– volume: 55
  start-page: 129
  year: 2014
  end-page: 135
  article-title: Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma
  publication-title: Int J Biochem Cell Biol
– volume: 60
  start-page: 576
  issue: 2
  year: 2014
  end-page: 587
  article-title: Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy
  publication-title: Hepatology
– volume: 10
  start-page: 8630
  issue: 24
  year: 2004
  end-page: 8640
  article-title: Mouse homologue of a novel human oncofetal antigen, glypican‐3, evokes T‐cell‐mediated tumor rejection without autoimmune reactions in mice
  publication-title: Clin Cancer Res
– volume: 18
  start-page: 3686
  issue: 13
  year: 2012
  end-page: 3696
  article-title: Phase I trial of a glypican‐3‐derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival
  publication-title: Clin Cancer Res
– volume: 100
  start-page: 1403
  issue: 8
  year: 2009
  end-page: 1407
  article-title: Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma
  publication-title: Cancer Sci
– volume: 14
  start-page: 157
  issue: 2
  year: 2015
  end-page: 163
  article-title: Prognostic value of glypican‐3 in patients with HBV‐associated hepatocellular carcinoma after liver transplantation
  publication-title: Hepatobiliary Pancreat Dis Int
– volume: 373
  start-page: 747
  issue: Pt 3
  year: 2003
  end-page: 757
  article-title: Zinc‐fingers and homeoboxes (ZHX) 2, a novel member of the ZHX family, functions as a transcriptional repressor
  publication-title: Biochem J
– volume: 28
  start-page: 497
  issue: 4
  year: 2011
  end-page: 503
  article-title: Inhibition of glypican‐3 expression via RNA interference influences the growth and invasive ability of the MHCC97‐H human hepatocellular carcinoma cell line
  publication-title: Int J Mol Med
– volume: 4
  start-page: 250
  issue: 3
  year: 2013
  end-page: 251
  article-title: Glypican‐4 is a new comer of adipokines working as insulin sensitizer
  publication-title: J Diabetes Investig
– volume: 50
  start-page: 122
  issue: 2
  year: 2011
  end-page: 135
  article-title: Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival
  publication-title: Genes Chromosomes Cancer
– volume: 519
  start-page: 187
  issue: 7542
  year: 2015
  end-page: 192
  article-title: Notum deacylates Wnt proteins to suppress signalling activity
  publication-title: Nature
– volume: 15
  start-page: 740
  issue: 6
  year: 2003
  end-page: 746
  article-title: Epithelial‐mesenchymal transitions in development and pathologies
  publication-title: Curr Opin Cell Biol
– volume: 15
  start-page: 162
  issue: 3
  year: 2011
  end-page: 169
  article-title: Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma
  publication-title: Ann Diagn Pathol
– volume: 89
  start-page: 418
  issue: 5
  year: 2000
  end-page: 422
  article-title: Expression of glypican 3 (GPC3) in embryonal tumors
  publication-title: Int J Cancer
– volume: 163C
  start-page: 92
  issue: 2
  year: 2013
  end-page: 105
  article-title: Phenotypic spectrum of Simpson‐Golabi‐Behmel syndrome in a series of 42 cases with a mutation in GPC3 and review of the literature
  publication-title: Am J Med Genet C Semin Med Genet
– volume: 40
  start-page: 1356
  issue: 3
  year: 2012
  end-page: 1365
  article-title: Molecular basis of differential target regulation by miR‐96 and miR‐182: The glypican‐3 as a model
  publication-title: Nucleic Acids Res
– volume: 55
  start-page: 799
  issue: 5
  year: 2014
  end-page: 804
  article-title: Glypican‐3‐targeted Zr‐89 PET imaging of hepatocellular carcinoma
  publication-title: J Nucl Med
– volume: 19
  start-page: 3655
  issue: 19
  year: 2015
  end-page: 3673
  article-title: Diagnosis accuracy of serum glypican‐3 level in patients with hepatocellular carcinoma and liver cirrhosis: A meta‐analysis
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 22
  start-page: 1343
  issue: 8
  year: 2013
  end-page: 1352
  article-title: Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 8
  start-page: 580
  issue: 4
  year: 2009
  end-page: 588
  article-title: Paths of FGFR‐driven tumorigenesis
  publication-title: Cell Cycle
– volume: 12
  start-page: 241
  issue: 3
  year: 1996
  end-page: 247
  article-title: Mutations in GPC3, a glypican gene, cause the Simpson‐Golabi‐Behmel overgrowth syndrome
  publication-title: Nat Genet
– volume: 128
  start-page: 2246
  issue: 9
  year: 2011
  end-page: 2247
  article-title: Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro
  publication-title: Int J Cancer
– volume: 7
  start-page: 79736
  issue: 48
  year: 2016
  end-page: 79746
  article-title: Glypican‐5 suppresses epithelial‐mesenchymal transition of the lung adenocarcinoma by competitively binding to Wnt3a
  publication-title: Oncotarget
– volume: 4
  start-page: 64
  issue: 4
  year: 2016
  article-title: Glypican‐1 in exosomes as biomarker for early detection of pancreatic cancer
  publication-title: Ann. Transl Med
– volume: 225
  start-page: 179
  issue: 1
  year: 2000
  end-page: 187
  article-title: Glypican‐3 controls cellular responses to Bmp4 in limb patterning and skeletal development
  publication-title: Dev Biol
– volume: 25
  start-page: 129
  issue: 1
  year: 2010
  end-page: 137
  article-title: Diagnostic role of serum glypican‐3 in differentiating hepatocellular carcinoma from non‐malignant chronic liver disease and other liver cancers
  publication-title: J Gastroenterol Hepatol
– volume: 19
  start-page: 920
  issue: 4
  year: 2013
  end-page: 928
  article-title: First‐in‐man phase I study of GC33, a novel recombinant humanized antibody against glypican‐3, in patients with advanced hepatocellular carcinoma
  publication-title: Clin Cancer Res
– volume: 54
  start-page: e1
  issue: 1
  year: 2016
  end-page: 2
  article-title: Glypican‐1 as a highly sensitive and specific pancreatic cancer biomarker
  publication-title: Clin Chem Lab Med
– volume: 14
  start-page: 700
  issue: 5
  year: 2008
  end-page: 711
  article-title: Glypican‐3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding
  publication-title: Dev Cell
– volume: 103
  start-page: 455
  issue: 4
  year: 2003
  end-page: 465
  article-title: Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling
  publication-title: Int J Cancer
– volume: 15
  start-page: 780
  issue: 6
  year: 2016
  end-page: 786
  article-title: Assessment of the clinical utility of glypican 3 as a serum marker for the diagnosis of hepatocellular carcinoma
  publication-title: Technol Cancer Res Treat
– volume: 192
  start-page: 691
  issue: 4
  year: 2011
  end-page: 704
  article-title: Glypican‐5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
  publication-title: J Cell Biol
– volume: 68
  start-page: 9832
  issue: 23
  year: 2008
  end-page: 9838
  article-title: Anti‐glypican 3 antibody as a potential antitumor agent for human liver cancer
  publication-title: Cancer Res
– volume: 67
  start-page: 57
  issue: 1
  year: 2007
  end-page: 65
  article-title: Role for amplification and expression of glypican‐5 in rhabdomyosarcoma
  publication-title: Cancer Res
– volume: 8
  start-page: 2329
  issue: 24
  year: 2009
  end-page: 2338
  article-title: Involvement of glypican‐3 in the recruitment of M2‐polarized tumor‐associated macrophages in hepatocellular carcinoma
  publication-title: Cancer Biol Ther
– volume: 19
  start-page: 778
  issue: 6
  year: 2013
  end-page: 788
  article-title: MicroRNA‐1291‐mediated silencing of IRE1 alpha enhances glypican‐3 expression
  publication-title: RNA
– volume: 110
  start-page: E1083
  issue: 12
  year: 2013
  end-page: E1091
  article-title: Therapeutically targeting glypican‐3 via a conformation‐specific single‐domain antibody in hepatocellular carcinoma
  publication-title: Proc Natl Acad Sci U S A
– volume: 98
  start-page: 2897
  issue: 7
  year: 2013
  end-page: 2901
  article-title: Association of glypican‐4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease
  publication-title: J Clin Endocrinol Metab
– volume: 8
  start-page: 930
  issue: 10
  year: 2009
  end-page: 938
  article-title: Histopathological analyses of the antitumor activity of anti‐glypican‐3 antibody (GC33) in human liver cancer xenograft models
  publication-title: Cancer Biol Ther
– volume: 6
  start-page: 559
  issue: 7
  year: 2006
  end-page: 565
  article-title: Immunotoxin therapy of cancer
  publication-title: Nat Rev Cancer
– volume: 586
  start-page: 884
  issue: 6
  year: 2012
  end-page: 891
  article-title: MiR‐219‐5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican‐3
  publication-title: FEBS Lett
– volume: 129
  start-page: 899
  issue: 6
  year: 2008
  end-page: 906
  article-title: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
  publication-title: Am J Clin Pathol
– volume: 7
  start-page: 42150
  issue: 27
  year: 2016
  end-page: 42158
  article-title: Expression of oncofetal antigen glypican‐3 associates significantly with poor prognosis in HBV‐related hepatocellular carcinoma
  publication-title: Oncotarget
– volume: 10
  start-page: 1139
  issue: 7
  year: 2015
  end-page: 1147
  article-title: Photoimmunotherapy of hepatocellular carcinoma‐targeting glypican‐3 combined with nanosized albumin‐bound paclitaxel
  publication-title: Nanomedicine
– volume: 4
  start-page: 15
  year: 2014
  article-title: Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade
  publication-title: Front Oncol
– volume: 410
  start-page: 503
  issue: 3
  year: 2008
  end-page: 511
  article-title: Mammalian Notum induces the release of glypicans and other GPI‐anchored proteins from the cell surface
  publication-title: Biochem J
– volume: 138
  start-page: 203
  issue: 2
  year: 2012
  end-page: 210
  article-title: Arginase‐1, HepPar‐1, and glypican‐3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine‐needle aspiration specimens
  publication-title: Am J Clin Pathol
– volume: 45
  start-page: 580
  issue: 7
  year: 2014
  end-page: 588
  article-title: Diagnosis accuracy of serum glypican‐3 in patients with hepatocellular carcinoma: A systematic review with meta‐analysis
  publication-title: Arch Med Res
– volume: 115
  start-page: 66
  issue: 1
  year: 2016
  end-page: 75
  article-title: Overexpression of glypican‐1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
  publication-title: Br J Cancer
– volume: 10
  start-page: 3177
  issue: 6
  year: 2014
  end-page: 3184
  article-title: Silencing of the glypican‐3 gene affects the biological behavior of human hepatocellular carcinoma cells
  publication-title: Mol Med Rep
– volume: 50
  start-page: 221
  issue: 3
  year: 2014
  end-page: 226
  article-title: Role of serum glypican‐3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis‐C virus cirrhosis
  publication-title: Alexandria J Med
– volume: 5
  start-page: e1129483
  issue: 5
  year: 2016
  article-title: Phase II study of the GPC3‐derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
  publication-title: Oncoimmunology
– volume: 29
  start-page: 1056
  issue: 7
  year: 2009
  end-page: 1064
  article-title: The expression profile of glypican‐3 and its relation to macrophage population in human hepatocellular carcinoma
  publication-title: Liver Int
– volume: 53
  start-page: 2086
  issue: 6
  year: 2011
  end-page: 2096
  article-title: Yes‐associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice
  publication-title: Hepatology
– volume: 3
  start-page: 584
  issue: 3
  year: 2015
  end-page: 590
  article-title: Diagnostic and prognostic significance of glypican 5 and glypican 6 gene expression levels in gastric adenocarcinoma
  publication-title: Mol Clin Oncol
– volume: 10
  start-page: 69
  issue: 1
  year: 2011
  end-page: 77
  article-title: Glypican‐3 targeting of liver cancer cells using multifunctional nanoparticles
  publication-title: Mol Imaging
– volume: 23
  start-page: 1333
  issue: 11
  year: 2008
  end-page: 1340
  article-title: Expression pattern of glypican‐3 (GPC3) during human embryonic and fetal development
  publication-title: Histol Histopathol
– volume: 9
  start-page: 1321
  issue: 9
  year: 2000
  end-page: 1328
  article-title: Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson‐Golabi‐Behmel syndrome: Identification of loss‐of‐function mutations in the GPC3 gene
  publication-title: Hum Mol Genet
– volume: 109
  start-page: 1031
  issue: 4
  year: 2013
  end-page: 1039
  article-title: Expression pattern of tumour‐associated antigens in hepatocellular carcinoma: Association with immune infiltration and disease progression
  publication-title: Br J Cancer
– volume: 8
  start-page: 14351
  year: 2017
  article-title: alpha3 Chains of type V collagen regulate breast tumour growth via glypican‐1
  publication-title: Nat Commun
– volume: 7
  start-page: 1002
  issue: 8
  year: 2016
  end-page: 1009
  article-title: Glypican‐1 as a Biomarker for Prostate Cancer: Isolation and Characterization
  publication-title: J Cancer
– volume: 46
  start-page: 1275
  issue: 3
  year: 2015
  end-page: 1285
  article-title: Glypican‐3 promotes epithelial‐mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway
  publication-title: Int J Oncol
– volume: 10
  start-page: 289
  issue: 3
  year: 2011
  end-page: 294
  article-title: Oncofetal antigen glypican‐3 as a promising early diagnostic marker for hepatocellular carcinoma
  publication-title: Hepatobiliary Pancreat Dis Int
– volume: 65
  start-page: 6245
  issue: 14
  year: 2005
  end-page: 6254
  article-title: Glypican‐3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling
  publication-title: Cancer Res
– volume: 12
  start-page: 853
  issue: 4
  year: 2016
  end-page: 869
  article-title: Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
  publication-title: Nanomedicine
– volume: 125
  start-page: 89
  issue: 1
  year: 2003
  end-page: 97
  article-title: Glypican‐3: A novel serum and histochemical marker for hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 126
  start-page: 1291
  issue: 6
  year: 2010
  end-page: 1301
  article-title: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo
  publication-title: Int J Cancer
– volume: 9
  start-page: e87120
  issue: 1
  year: 2014
  article-title: Dysplastic nodules with glypican‐3 positive immunostaining: A risk for early hepatocellular carcinoma
  publication-title: PloS One
– volume: 8
  start-page: 505
  issue: 9
  year: 2012
  article-title: Obesity: Glypican‐4: Role in insulin signalling
  publication-title: Nat Rev Endocrinol
– volume: 132
  start-page: 1723
  issue: 11
  year: 2008
  end-page: 1728
  article-title: Glypican‐3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions
  publication-title: Arch Pathol Lab Med
– volume: 280
  start-page: 2116
  issue: 3
  year: 2005
  end-page: 2125
  article-title: The loss of glypican‐3 induces alterations in Wnt signaling
  publication-title: J Biol Chem
– volume: 419
  start-page: 656
  issue: 4
  year: 2012
  end-page: 661
  article-title: Silencing glypican‐3 expression induces apoptosis in human hepatocellular carcinoma cells
  publication-title: Biochem Biophys Res Commun
– volume: 12
  start-page: 477
  issue: 4
  year: 2016
  end-page: 487
  article-title: Iron‐oxide‐based nanovector for tumor targeted siRNA delivery in an orthotopic hepatocellular carcinoma xenograft mouse model
  publication-title: Small
– volume: 61
  start-page: 278
  issue: 130
  year: 2014
  end-page: 284
  article-title: GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice
  publication-title: Hepatogastroenterology
– volume: 131
  start-page: 1758
  issue: 6
  year: 2006
  end-page: 1767
  article-title: A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
  publication-title: Gastroenterology
– volume: 163
  start-page: 625
  issue: 3
  year: 2003
  end-page: 635
  article-title: Processing by proprotein convertases is required for glypican‐3 modulation of cell survival, Wnt signaling, and gastrulation movements
  publication-title: J Cell Biol
– volume: 35
  start-page: 5857
  issue: 6
  year: 2014
  end-page: 5868
  article-title: Glypican‐3 as an emerging molecular target for hepatocellular carcinoma gene therapy
  publication-title: Tumor Biol
– volume: 19
  start-page: S455
  issue: Suppl 3
  year: 2012
  end-page: 463
  article-title: Recurrence and poor prognosis following resection of small hepatitis B‐related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin
  publication-title: Ann Surg Oncol
– volume: 4
  start-page: 71
  issue: 1
  year: 2004
  end-page: 78
  article-title: Tumour‐educated macrophages promote tumour progression and metastasis
  publication-title: Nat Rev Cancer
– volume: 149
  start-page: 1042
  issue: 4
  year: 2015
  end-page: 1052
  article-title: T cells engineered to express a T‐cell receptor specific for glypican‐3 to recognize and kill hepatoma cells in vitro and in mice
  publication-title: Gastroenterology
– volume: 272
  start-page: 7574
  issue: 12
  year: 1997
  end-page: 7577
  article-title: OCI‐5/rat glypican‐3 binds to fibroblast growth factor‐2 but not to insulin‐like growth factor‐2
  publication-title: J Biol Chem
– volume: 64
  start-page: 2418
  issue: 7
  year: 2004
  end-page: 2423
  article-title: Identification of soluble NH2‐terminal fragment of glypican‐3 as a serological marker for early‐stage hepatocellular carcinoma
  publication-title: Cancer Res
– volume: 11
  start-page: 19R
  issue: 3
  year: 2001
  end-page: 23R
  article-title: Glypicans in growth control and cancer
  publication-title: Glycobiology
– volume: 47
  start-page: 196
  issue: 3
  year: 2014
  end-page: 200
  article-title: Diagnostic accuracy of serum glypican‐3 for hepatocellular carcinoma: A systematic review and meta‐analysis
  publication-title: Clin Biochem
– volume: 137
  start-page: 1643
  issue: 7
  year: 2015
  end-page: 1651
  article-title: High preoperative levels of serum glypican‐3 containing N‐terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy
  publication-title: Int J Cancer
– volume: 11
  start-page: 195
  issue: 3
  year: 2011
  end-page: 199
  article-title: Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT
  publication-title: Hepat Mon
– volume: 8
  start-page: 177
  issue: 2
  year: 2014
  end-page: 185
  article-title: Clinical utility of plasma glypican‐3 and osteopontin as biomarkers of hepatocellular carcinoma
  publication-title: Gut Liver
– volume: 13
  start-page: 703
  issue: 3
  year: 2013
  end-page: 709
  article-title: Diagnostic value of glypican‐3 in alpha fetoprotein negative hepatocellular carcinoma patients
  publication-title: Afr Health Sci
– volume: 65
  start-page: 289
  issue: 2
  year: 2016
  end-page: 295
  article-title: Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
  publication-title: J Hepatol
– volume: 35
  start-page: 6964
  issue: 25
  year: 2014
  end-page: 6971
  article-title: Imaging of hepatocellular carcinoma patient‐derived xenografts using Zr‐89‐labeled anti‐glypican‐3 monoclonal antibody
  publication-title: Biomaterials
– volume: 116
  start-page: 1582
  issue: 6
  year: 2006
  end-page: 1595
  article-title: Met‐regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
  publication-title: J Clin Investig
– volume: 25
  start-page: 962
  issue: 5
  year: 2005
  end-page: 966
  article-title: Upregulation of glypican‐3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers
  publication-title: Liver Int
– volume: 22
  start-page: 275
  issue: 1
  year: 2016
  end-page: 283
  article-title: Glypican‐3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
  publication-title: World J Gastroenterol
– volume: 11
  start-page: 29
  issue: 1
  year: 2011
  end-page: 39
  article-title: Application of HBx‐induced anti‐URGs as early warning biomarker of cirrhosis and HCC
  publication-title: Cancer Biomark
– volume: 16
  start-page: 3521
  issue: 28
  year: 2010
  end-page: 3528
  article-title: Association of glypican‐3 expression with growth signaling molecules in hepatocellular carcinoma
  publication-title: World J Gastroenterol
– volume: 56
  start-page: 1380
  issue: 4
  year: 2012
  end-page: 1390
  article-title: Oncogenic activation of glypican‐3 by c‐Myc in human hepatocellular carcinoma
  publication-title: Hepatology
– volume: 125
  start-page: 740
  issue: 5
  year: 2006
  end-page: 746
  article-title: Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma
  publication-title: Am J Clin Pathol
– volume: 31
  start-page: 120
  issue: 1
  year: 2011
  end-page: 131
  article-title: Prognostic significance of circumferential cell surface immunoreactivity of glypican‐3 in hepatocellular carcinoma
  publication-title: Liver Int
– volume: 10
  start-page: 415
  issue: 6
  year: 2010
  end-page: 424
  article-title: TGFbeta signalling: A complex web in cancer progression
  publication-title: Nat Rev Cancer
– volume: 46
  start-page: 1541
  issue: 5
  year: 2007
  end-page: 1547
  article-title: The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha‐fetoprotein regulator 2
  publication-title: Hepatology
– volume: 42
  start-page: 831
  issue: 3
  year: 2013
  end-page: 838
  article-title: Identification of an H2‐Kb or H2‐Db restricted and glypican‐3‐derived cytotoxic T‐lymphocyte epitope peptide
  publication-title: Int J Oncol
– volume: 18
  start-page: 2408
  issue: 19
  year: 2012
  end-page: 2414
  article-title: Glypican‐3 expression and its relationship with recurrence of HCC after liver transplantation
  publication-title: World J Gastroenterol
– volume: 282
  start-page: 152
  issue: 1
  year: 2005
  end-page: 162
  article-title: Altered hematopoiesis in glypican‐3‐deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification
  publication-title: Dev Biol
– volume: 11
  start-page: 3361
  issue: 5
  year: 2015
  end-page: 3367
  article-title: Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co‐cultured with cytokine‐induced killer cells against hepatocellular carcinoma cells
  publication-title: Mol Med Rep
– volume: 12
  start-page: 171
  issue: 2
  year: 2013
  end-page: 179
  article-title: Values of circulating GPC‐3 mRNA and alpha‐fetoprotein in detecting patients with hepatocellular carcinoma
  publication-title: Hepatobiliary Pancreat Dis
– volume: 1
  start-page: 14
  issue: 1
  year: 2011
  end-page: 19
  article-title: The role of glypican‐3 in regulating Wnt in hepatocellular carcinomas
  publication-title: Cancer Rep
– volume: 66
  start-page: 227
  issue: 2
  year: 1996
  end-page: 234
  article-title: Simpson‐Golabi‐Behmel syndrome: Genotype/phenotype analysis of 18 affected males from 7 unrelated families
  publication-title: Am J Med Genet
– volume: 44
  start-page: 338
  issue: 3
  year: 2014
  end-page: 348
  article-title: MicroRNA‐520c‐3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican‐3
  publication-title: Hepatol Res
– volume: 61
  start-page: 1481
  issue: 10
  year: 2012
  end-page: 1487
  article-title: Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
  publication-title: Gut
– volume: 12
  start-page: 2689
  issue: 9
  year: 2006
  end-page: 2697
  article-title: Identification of HLA‐A2‐or HLA‐A24‐restricted CTL epitopes possibly useful for glypican‐3‐specific immunotherapy of hepatocellular carcinoma
  publication-title: Clin Cancer Res
– volume: 124
  start-page: 208
  issue: 3
  year: 2016
  end-page: 215
  article-title: Expression profile and prognostic value of glypican‐3 in post‐operative South Korean hepatocellular carcinoma patients
  publication-title: APMIS
– volume: 55
  start-page: 2032
  issue: 12
  year: 2014
  end-page: 2037
  article-title: Glypican‐3‐targeting F(ab ')2 for Zr‐89 PET of hepatocellular carcinoma
  publication-title: J Nucl Med
– volume: 65
  start-page: 5991
  issue: 14
  year: 2005
  end-page: 5995
  article-title: Carcinoma invasion and metastasis: A role for epithelial‐mesenchymal transition?
  publication-title: Cancer Res
– volume: 57
  start-page: 195
  issue: 1
  year: 2013
  end-page: 204
  article-title: A functional screening identifies five microRNAs controlling glypican‐3: Role of miR‐1271 down‐regulation in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 11
  start-page: e0151501
  issue: 3
  year: 2016
  article-title: CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection
  publication-title: PloS One
– volume: 23
  start-page: 153
  issue: 2
  year: 2015
  end-page: 160
  article-title: Differential expression of glypican‐1 in ameloblastoma variants
  publication-title: Appl Immunohistochem Mol Morphol
– volume: 17
  start-page: 490
  issue: 6
  year: 2013
  end-page: 493
  article-title: Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions
  publication-title: Ann Diagn Pathol
– volume: 39
  start-page: 351
  issue: 1
  year: 2012
  end-page: 357
  article-title: Glypican‐3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients
  publication-title: Mol Biol Rep
– volume: 335
  start-page: 208
  issue: 1
  year: 2009
  end-page: 215
  article-title: Loss of glypican‐3 function causes growth factor‐dependent defects in cardiac and coronary vascular development
  publication-title: Dev Biol
– volume: 6
  start-page: 6536
  year: 2015
  article-title: Immunotoxin targeting glypican‐3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis
  publication-title: Nat Commun
– volume: 7
  start-page: 4593
  year: 2012
  end-page: 4611
  article-title: Preparation and in vitro studies of MRI‐specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma
  publication-title: Int J Nanomed
– volume: 46
  start-page: 28
  issue: 1
  year: 2015
  end-page: 36
  article-title: Programmed death‐1 blockade enhances the antitumor effects of peptide vaccine‐induced peptide‐specific cytotoxic T lymphocytes
  publication-title: Int J Oncol
– volume: 49
  start-page: 117
  issue: 1
  year: 2014
  end-page: 125
  article-title: Positive glypican‐3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
  publication-title: J Gastroenterol
– volume: 34
  start-page: 661
  issue: 2
  year: 2013
  end-page: 668
  article-title: Targeted glypican‐3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA
  publication-title: Tumor Biol
– volume: 29
  start-page: 85
  issue: 2
  year: 2015
  end-page: 93
  article-title: Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma
  publication-title: J Clin Lab Anal
– volume: 8
  start-page: 32450
  issue: 20
  year: 2017
  end-page: 32460
  article-title: Construction of an immunotoxin, HN3‐mPE24, targeting glypican‐3 for liver cancer therapy
  publication-title: Oncotarget
– volume: 32
  start-page: 38
  issue: 1
  year: 2012
  end-page: 47
  article-title: Deregulation of Hippo kinase signalling in human hepatic malignancies
  publication-title: Liver Int
– volume: 62
  start-page: 639
  issue: 4
  year: 2013
  end-page: 652
  article-title: Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: A potential option for improvement in antigen‐specific cancer immunotherapy
  publication-title: Cancer Immunol Immunother
– volume: 114
  start-page: 547
  issue: 6
  year: 2012
  end-page: 552
  article-title: Glypican‐3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray‐based study
  publication-title: Acta Histochem
– volume: 47
  start-page: 1211
  issue: 4
  year: 2008
  end-page: 1222
  article-title: Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 13
  start-page: 735
  issue: 8
  year: 2011
  end-page: 747
  article-title: Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up‐regulation of TGF‐beta2
  publication-title: Neoplasia
– volume: 14
  start-page: 7345
  issue: 12
  year: 2013
  end-page: 7349
  article-title: Can glypican‐3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
  publication-title: Asian Pac J Cancer Prev
– volume: 48
  start-page: 558
  issue: 4
  year: 2001
  end-page: 564
  article-title: Enhanced glypican‐3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
  publication-title: Gut
– volume: 20
  start-page: 6418
  issue: 24
  year: 2014
  end-page: 6428
  article-title: Development of T cells redirected to glypican‐3 for the treatment of hepatocellular carcinoma
  publication-title: Clin Cancer Res
– volume: 32
  start-page: 985
  issue: 5
  year: 2008
  end-page: 990
  article-title: HLA‐A2 and‐A24‐restricted glypican‐3‐derived peptide vaccine induces specific CTLs: Preclinical study using mice
  publication-title: Int J Oncol
– volume: 4
  start-page: 803
  issue: 6
  year: 2008
  end-page: 814
  article-title: Heparin‐degrading sulfatases in hepatocellular carcinoma: Roles in pathogenesis and therapy targets
  publication-title: Future Oncol
– volume: 9
  start-page: 1228
  issue: 6
  year: 2013
  end-page: 1233
  article-title: Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican‐3‐derived peptide vaccination An autopsy case
  publication-title: Hum Vacc Immunother
– volume: 27
  start-page: 831
  issue: 3
  year: 2016
  end-page: 839
  article-title: Novel glypican‐3‐binding peptide for in vivo hepatocellular carcinoma fluorescent imaging
  publication-title: Bioconjug Chem
– volume: 4
  start-page: 592
  issue: 5
  year: 2012
  end-page: 599
  article-title: High‐affinity monoclonal antibodies to cell surface tumor antigen glypican‐3 generated through a combination of peptide immunization and flow cytometry screening
  publication-title: mAbs
– volume: 379
  start-page: 1245
  issue: 9822
  year: 2012
  end-page: 1255
  article-title: Hepatocellular carcinoma
  publication-title: Lancet
– volume: 114
  start-page: 625
  issue: 3
  year: 2013
  end-page: 631
  article-title: Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down‐regulation of YAP
  publication-title: J Cell Biochem
– volume: 108
  start-page: 497
  issue: 4
  year: 2001
  end-page: 501
  article-title: Glypicans: Proteoglycans with a surprise
  publication-title: J. Clin Investig
– volume: 2
  start-page: 135
  issue: 4
  year: 2006
  end-page: 140
  article-title: Tumor‐associated macrophage: Its role in tumor angiogenesis
  publication-title: J Cancer Mol
– volume: 117
  start-page: 927
  issue: 7
  year: 2004
  end-page: 939
  article-title: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
  publication-title: Cell
– volume: 52
  start-page: 1680
  issue: 5
  year: 2010
  end-page: 1689
  article-title: The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3‐dependent Wnt activation
  publication-title: Hepatology
– volume: 280
  start-page: 41201
  issue: 50
  year: 2005
  end-page: 41206
  article-title: Processing by convertases is not required for glypican‐3‐induced stimulation of hepatocellular carcinoma growth
  publication-title: J Biol Chem
– volume: 7
  start-page: 77683
  issue: 47
  year: 2016
  end-page: 77695
  article-title: Integrin alpha2beta1 inhibits MST1 kinase phosphorylation and activates Yes‐associated protein oncogenic signaling in hepatocellular carcinoma
  publication-title: Oncotarget
– volume: 40
  start-page: 477
  issue: 5
  year: 2010
  end-page: 485
  article-title: Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with glypican‐3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma
  publication-title: Hepatol Res
– volume: 306
  start-page: 16
  issue: 1
  year: 2003
  end-page: 25
  article-title: Glypican‐3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
  publication-title: Biochem Biophys Res Commun
– volume: 112
  start-page: 240
  issue: 3
  year: 2010
  end-page: 250
  article-title: Optimization of tissue processing for immunohistochemistry for the detection of human glypican‐3
  publication-title: Acta Histochem
– volume: 58
  start-page: 1718
  issue: 110
  year: 2011
  end-page: 1724
  article-title: Simultaneous measurements of serum AFP; GPC‐3 and HCCR for diagnosing hepatocellular carcinoma
  publication-title: Hepatogastroenterology
– volume: 17
  issue: 4
  year: 2017
  article-title: Identification of a glypican‐3‐binding peptide for in vivo non‐invasive human hepatocellular carcinoma detection
  publication-title: Macromol Biosci
– volume: 45
  start-page: 725
  issue: 3
  year: 2007
  end-page: 734
  article-title: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
  publication-title: Hepatology
– volume: 378
  start-page: 279
  issue: 2
  year: 2009
  end-page: 284
  article-title: Anti‐glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
  publication-title: Biochem Biophys Res Commun
– volume: 25
  start-page: 113
  issue: 2
  year: 2011
  end-page: 117
  article-title: Detection of alpha‐fetoprotein and glypican‐3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ‐RT‐PCR
  publication-title: J Clin Lab Anal
– volume: 5
  start-page: e1062209
  issue: 1
  year: 2016
  article-title: Identification of glypican‐3‐derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
  publication-title: Oncoimmunology
– volume: 469
  start-page: 138
  issue: 1
  year: 2016
  end-page: 143
  article-title: Vaccination with liposome‐coupled glypican‐3‐derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3‐expressing tumor growth in mice
  publication-title: Biochem Biophys Res Commun
– volume: 21
  start-page: 224
  issue: 2
  year: 2006
  end-page: 228
  article-title: Cellular changes resulting from forced expression of glypican‐3 in hepatocellular carcinoma cells
  publication-title: Mol Cell
– volume: 423
  start-page: 105
  year: 2013
  end-page: 111
  article-title: Reevaluation of glypican‐3 as a serological marker for hepatocellular carcinoma
  publication-title: Clin Chim Acta
– volume: 107
  start-page: 1437
  issue: 4
  year: 2010
  end-page: 1442
  article-title: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver
  publication-title: Proc Natl Acad Sci U S A
– volume: 136
  start-page: E359
  issue: 5
  year: 2015
  end-page: E386
  article-title: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
  publication-title: Int J Cancer
– volume: 59
  start-page: 1107
  issue: 5
  year: 2013
  end-page: 1117
  article-title: Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs
  publication-title: J Hepatol
– volume: 37
  start-page: 1435
  issue: 11
  year: 2006
  end-page: 1441
  article-title: Glypican‐3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas
  publication-title: Human Pathol
– volume: 40
  start-page: 7069
  issue: 12
  year: 2013
  end-page: 7075
  article-title: Evaluation of circulating transforming growth factor‐beta1, glypican‐3 and Golgi protein‐73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients
  publication-title: Mol Biol Rep
– volume: 127
  start-page: 1565
  issue: Pt 7
  year: 2014
  end-page: 1575
  article-title: Glypican‐3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
  publication-title: J Cell Sci
– volume: 18
  start-page: 121
  issue: 1
  year: 2017
  end-page: 127
  article-title: Differential expression of glypican‐3 and insulin‐like growth factor‐II mRNAs and alpha‐fetoprotein and Ki‐67 markers in HCV related hepatocellular carcinomas in Egyptian patients
  publication-title: Asian Pac J Cancer Prev
– volume: 6
  start-page: 108
  year: 2016
  end-page: 112
  article-title: Glypican‐5 is a tumor suppressor in non‐small cell lung cancer cells
  publication-title: Biochem Biophys Rep
– volume: 12
  start-page: 2151
  issue: 6
  year: 2015
  end-page: 2157
  article-title: Glypican‐3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy
  publication-title: Mol Pharmaceut
– volume: 107
  start-page: 8248
  issue: 18
  year: 2010
  end-page: 8253
  article-title: The Hippo‐Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
  publication-title: Proc Natl Acad Sci U S A
– ident: e_1_2_12_147_1
  doi: 10.1016/j.bbrc.2015.11.084
– ident: e_1_2_12_109_1
  doi: 10.1002/ijc.29518
– ident: e_1_2_12_87_1
  doi: 10.2217/14796694.4.6.803
– ident: e_1_2_12_75_1
  doi: 10.1002/hep.25891
– ident: e_1_2_12_92_1
  doi: 10.1016/j.febslet.2012.02.017
– ident: e_1_2_12_131_1
  doi: 10.1016/j.bbrc.2008.11.033
– ident: e_1_2_12_42_1
  doi: 10.1074/jbc.272.12.7574
– ident: e_1_2_12_166_1
  doi: 10.1016/j.acthis.2011.10.003
– ident: e_1_2_12_86_1
  doi: 10.1002/hep.23848
– ident: e_1_2_12_81_1
  doi: 10.1042/bj20030171
– ident: e_1_2_12_62_1
  doi: 10.1002/hep.26996
– ident: e_1_2_12_10_1
  doi: 10.1093/glycob/11.3.19R
– ident: e_1_2_12_102_1
  doi: 10.1136/gutjnl-2011-301862
– ident: e_1_2_12_165_1
  doi: 10.1371/journal.pone.0087120
– volume: 19
  start-page: S455
  issue: 3
  year: 2012
  ident: e_1_2_12_128_1
  article-title: Recurrence and poor prognosis following resection of small hepatitis B‐related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin
  publication-title: Ann Surg Oncol
– volume: 21
  start-page: 224
  issue: 2
  year: 2006
  ident: e_1_2_12_66_1
  article-title: Cellular changes resulting from forced expression of glypican‐3 in hepatocellular carcinoma cells
  publication-title: Mol Cell
  doi: 10.1016/S1016-8478(23)12884-6
– volume: 8
  start-page: 32450
  issue: 20
  year: 2017
  ident: e_1_2_12_152_1
  article-title: Construction of an immunotoxin, HN3‐mPE24, targeting glypican‐3 for liver cancer therapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10592
– ident: e_1_2_12_59_1
  doi: 10.1002/hep.22202
– ident: e_1_2_12_74_1
  doi: 10.3892/ijo.2015.2827
– volume: 7
  start-page: 1002
  issue: 8
  year: 2016
  ident: e_1_2_12_21_1
  article-title: Glypican‐1 as a Biomarker for Prostate Cancer: Isolation and Characterization
  publication-title: J Cancer
  doi: 10.7150/jca.14645
– ident: e_1_2_12_69_1
  doi: 10.1111/j.1478-3231.2008.01968.x
– ident: e_1_2_12_145_1
  doi: 10.3892/ijo.2013.1793
– ident: e_1_2_12_96_1
  doi: 10.1016/S1499-3872(11)60048-9
– ident: e_1_2_12_171_1
  doi: 10.1016/S1499-3872(13)60028-4
– volume: 19
  start-page: 3655
  issue: 19
  year: 2015
  ident: e_1_2_12_111_1
  article-title: Diagnosis accuracy of serum glypican‐3 level in patients with hepatocellular carcinoma and liver cirrhosis: A meta‐analysis
  publication-title: Eur Rev Med Pharmacol Sci
– ident: e_1_2_12_8_1
  doi: 10.1158/1078-0432.CCR-12-2616
– ident: e_1_2_12_158_1
  doi: 10.1002/smll.201501985
– volume: 54
  start-page: e1
  issue: 1
  year: 2016
  ident: e_1_2_12_17_1
  article-title: Glypican‐1 as a highly sensitive and specific pancreatic cancer biomarker
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2015-0773
– ident: e_1_2_12_146_1
  doi: 10.1080/2162402X.2015.1062209
– ident: e_1_2_12_47_1
  doi: 10.1002/ajmg.c.31360
– volume: 7
  start-page: 79736
  issue: 48
  year: 2016
  ident: e_1_2_12_34_1
  article-title: Glypican‐5 suppresses epithelial‐mesenchymal transition of the lung adenocarcinoma by competitively binding to Wnt3a
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12945
– ident: e_1_2_12_123_1
  doi: 10.1016/j.surg.2013.02.014
– volume: 18
  start-page: 121
  issue: 1
  year: 2017
  ident: e_1_2_12_97_1
  article-title: Differential expression of glypican‐3 and insulin‐like growth factor‐II mRNAs and alpha‐fetoprotein and Ki‐67 markers in HCV related hepatocellular carcinomas in Egyptian patients
  publication-title: Asian Pac J Cancer Prev
– ident: e_1_2_12_132_1
  doi: 10.4161/cbt.8.10.8149
– volume: 7
  start-page: 77683
  issue: 47
  year: 2016
  ident: e_1_2_12_78_1
  article-title: Integrin alpha2beta1 inhibits MST1 kinase phosphorylation and activates Yes‐associated protein oncogenic signaling in hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12760
– ident: e_1_2_12_159_1
  doi: 10.2217/nnm.14.194
– ident: e_1_2_12_43_1
  doi: 10.1016/j.devcel.2008.03.006
– ident: e_1_2_12_172_1
  doi: 10.1111/j.1440-1746.2009.05988.x
– ident: e_1_2_12_154_1
  doi: 10.1007/s13277-012-0593-y
– ident: e_1_2_12_79_1
  doi: 10.1111/j.1478-3231.2011.02646.x
– ident: e_1_2_12_85_1
  doi: 10.1002/gcc.20838
– volume: 7
  start-page: 4593
  year: 2012
  ident: e_1_2_12_117_1
  article-title: Preparation and in vitro studies of MRI‐specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma
  publication-title: Int J Nanomed
– ident: e_1_2_12_93_1
  doi: 10.1002/ijc.24941
– ident: e_1_2_12_28_1
  doi: 10.1210/jc.2012-4297
– volume: 23
  start-page: 153
  issue: 2
  year: 2015
  ident: e_1_2_12_20_1
  article-title: Differential expression of glypican‐1 in ameloblastoma variants
  publication-title: Appl Immunohistochem Mol Morphol
  doi: 10.1097/PAI.0000000000000042
– ident: e_1_2_12_65_1
  doi: 10.1593/neo.11664
– ident: e_1_2_12_83_1
  doi: 10.1016/j.biocel.2014.08.021
– ident: e_1_2_12_37_1
  doi: 10.1042/BJ20070511
– ident: e_1_2_12_5_1
  doi: 10.1111/j.1349-7006.2009.01206.x
– volume: 32
  start-page: 359
  issue: 1
  year: 2015
  ident: e_1_2_12_167_1
  article-title: Reevaluation of glypican‐3 as a prognostic marker in HCC using X‐tile software
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0359-z
– volume: 55
  start-page: 799
  issue: 5
  year: 2014
  ident: e_1_2_12_115_1
  article-title: Glypican‐3‐targeted Zr‐89 PET imaging of hepatocellular carcinoma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.113.132118
– ident: e_1_2_12_133_1
  doi: 10.1111/cas.12368
– ident: e_1_2_12_142_1
  doi: 10.4161/hv.24179
– ident: e_1_2_12_119_1
  doi: 10.1021/acs.bioconjchem.6b00030
– ident: e_1_2_12_95_1
  doi: 10.1016/j.ajme.2014.01.002
– volume: 55
  start-page: 2032
  issue: 12
  year: 2014
  ident: e_1_2_12_116_1
  article-title: Glypican‐3‐targeting F(ab ')2 for Zr‐89 PET of hepatocellular carcinoma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.114.145102
– ident: e_1_2_12_143_1
  doi: 10.1158/1078-0432.CCR-11-3044
– ident: e_1_2_12_100_1
  doi: 10.1002/hep.21531
– ident: e_1_2_12_104_1
  doi: 10.1016/j.anndiagpath.2013.08.001
– volume: 57
  start-page: 5179
  issue: 22
  year: 1997
  ident: e_1_2_12_40_1
  article-title: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution
  publication-title: Cancer Res
– ident: e_1_2_12_80_1
  doi: 10.1073/pnas.0911427107
– volume: 58
  start-page: 1718
  issue: 110
  year: 2011
  ident: e_1_2_12_173_1
  article-title: Simultaneous measurements of serum AFP; GPC‐3 and HCCR for diagnosing hepatocellular carcinoma
  publication-title: Hepatogastroenterology
– ident: e_1_2_12_50_1
  doi: 10.1006/dbio.2000.9831
– volume: 4
  start-page: 64
  issue: 4
  year: 2016
  ident: e_1_2_12_16_1
  article-title: Glypican‐1 in exosomes as biomarker for early detection of pancreatic cancer
  publication-title: Ann. Transl Med
– ident: e_1_2_12_71_1
  doi: 10.1016/j.cell.2004.06.006
– ident: e_1_2_12_174_1
  doi: 10.5009/gnl.2014.8.2.177
– ident: e_1_2_12_31_1
  doi: 10.1083/jcb.201008087
– ident: e_1_2_12_14_1
  doi: 10.1172/JCI200113712
– ident: e_1_2_12_94_1
  doi: 10.1002/ijc.25549
– ident: e_1_2_12_155_1
  doi: 10.1007/s13277-014-1776-5
– volume: 6
  start-page: 108
  year: 2016
  ident: e_1_2_12_33_1
  article-title: Glypican‐5 is a tumor suppressor in non‐small cell lung cancer cells
  publication-title: Biochem Biophys Rep
– ident: e_1_2_12_13_1
  doi: 10.1016/j.humpath.2006.05.016
– volume: 9
  start-page: 224.1
  issue: 5
  year: 2008
  ident: e_1_2_12_15_1
  article-title: Glypicans
  publication-title: Genome Biol
  doi: 10.1186/gb-2008-9-5-224
– ident: e_1_2_12_53_1
  doi: 10.1016/S0006-291X(03)00908-2
– ident: e_1_2_12_110_1
  doi: 10.1158/1055-9965.EPI-13-0179
– ident: e_1_2_12_137_1
  doi: 10.1021/acs.molpharmaceut.5b00132
– ident: e_1_2_12_38_1
  doi: 10.1038/nature14259
– ident: e_1_2_12_18_1
  doi: 10.1038/ncomms14351
– ident: e_1_2_12_58_1
  doi: 10.4161/cc.8.4.7657
– ident: e_1_2_12_129_1
  doi: 10.1371/journal.pone.0151501
– ident: e_1_2_12_170_1
  doi: 10.1002/jcla.20443
– ident: e_1_2_12_60_1
  doi: 10.1002/hep.510250413
– volume: 10
  start-page: 8630
  issue: 24
  year: 2004
  ident: e_1_2_12_138_1
  article-title: Mouse homologue of a novel human oncofetal antigen, glypican‐3, evokes T‐cell‐mediated tumor rejection without autoimmune reactions in mice
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1177
– ident: e_1_2_12_125_1
  doi: 10.1016/S1499-3872(15)60349-6
– ident: e_1_2_12_148_1
  doi: 10.3892/ijo.2014.2737
– volume: 129
  start-page: 899
  issue: 6
  year: 2008
  ident: e_1_2_12_26_1
  article-title: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
  publication-title: Am J Clin Pathol
  doi: 10.1309/HCQWPWD50XHD2DW6
– volume: 61
  start-page: 278
  issue: 130
  year: 2014
  ident: e_1_2_12_149_1
  article-title: GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice
  publication-title: Hepatogastroenterology
– volume: 2
  start-page: 135
  issue: 4
  year: 2006
  ident: e_1_2_12_67_1
  article-title: Tumor‐associated macrophage: Its role in tumor angiogenesis
  publication-title: J Cancer Mol
– ident: e_1_2_12_99_1
  doi: 10.1111/j.1478-3231.2010.02359.x
– ident: e_1_2_12_134_1
  doi: 10.1016/j.jhep.2016.04.004
– ident: e_1_2_12_162_1
  doi: 10.3892/mmr.2015.3239
– ident: e_1_2_12_76_1
  doi: 10.1073/pnas.0912203107
– ident: e_1_2_12_168_1
  doi: 10.1038/bjc.2013.390
– ident: e_1_2_12_112_1
  doi: 10.1016/j.arcmed.2014.11.002
– ident: e_1_2_12_122_1
  doi: 10.1007/s11033-011-0745-y
– volume: 23
  start-page: 1333
  issue: 11
  year: 2008
  ident: e_1_2_12_9_1
  article-title: Expression pattern of glypican‐3 (GPC3) during human embryonic and fetal development
  publication-title: Histol Histopathol
– volume: 12
  start-page: 2689
  issue: 9
  year: 2006
  ident: e_1_2_12_139_1
  article-title: Identification of HLA‐A2‐or HLA‐A24‐restricted CTL epitopes possibly useful for glypican‐3‐specific immunotherapy of hepatocellular carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2267
– ident: e_1_2_12_4_1
  doi: 10.1016/j.nano.2015.12.381
– ident: e_1_2_12_45_1
  doi: 10.1038/ng0396-241
– ident: e_1_2_12_48_1
  doi: 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U
– ident: e_1_2_12_150_1
  doi: 10.1038/nrc1891
– ident: e_1_2_12_82_1
  doi: 10.1002/hep.21825
– ident: e_1_2_12_176_1
  doi: 10.1002/jcla.21733
– ident: e_1_2_12_169_1
  doi: 10.1016/j.anndiagpath.2010.10.004
– volume: 32
  start-page: 985
  issue: 5
  year: 2008
  ident: e_1_2_12_140_1
  article-title: HLA‐A2 and‐A24‐restricted glypican‐3‐derived peptide vaccine induces specific CTLs: Preclinical study using mice
  publication-title: Int J Oncol
– ident: e_1_2_12_84_1
  doi: 10.1309/09B452V7R76K7D6K
– volume: 11
  start-page: 195
  issue: 3
  year: 2011
  ident: e_1_2_12_127_1
  article-title: Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT
  publication-title: Hepat Mon
– volume: 10
  start-page: 69
  issue: 1
  year: 2011
  ident: e_1_2_12_118_1
  article-title: Glypican‐3 targeting of liver cancer cells using multifunctional nanoparticles
  publication-title: Mol Imaging
– ident: e_1_2_12_73_1
  doi: 10.1016/j.ceb.2003.10.006
– ident: e_1_2_12_157_1
  doi: 10.1016/j.bbrc.2012.02.069
– ident: e_1_2_12_46_1
  doi: 10.1093/hmg/9.9.1321
– volume: 17
  issue: 4
  year: 2017
  ident: e_1_2_12_120_1
  article-title: Identification of a glypican‐3‐binding peptide for in vivo non‐invasive human hepatocellular carcinoma detection
  publication-title: Macromol Biosci
– ident: e_1_2_12_151_1
  doi: 10.1038/ncomms7536
– volume: 11
  start-page: 29
  issue: 1
  year: 2011
  ident: e_1_2_12_106_1
  article-title: Application of HBx‐induced anti‐URGs as early warning biomarker of cirrhosis and HCC
  publication-title: Cancer Biomark
  doi: 10.3233/CBM-2012-0261
– ident: e_1_2_12_114_1
  doi: 10.1016/j.biomaterials.2014.04.089
– ident: e_1_2_12_24_1
  doi: 10.1158/0008-5472.CAN-04-4244
– volume: 16
  start-page: 3521
  issue: 28
  year: 2010
  ident: e_1_2_12_57_1
  article-title: Association of glypican‐3 expression with growth signaling molecules in hepatocellular carcinoma
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v16.i28.3521
– ident: e_1_2_12_70_1
  doi: 10.1038/nrc1256
– ident: e_1_2_12_6_1
  doi: 10.1002/ijc.10856
– volume: 280
  start-page: 41201
  issue: 50
  year: 2005
  ident: e_1_2_12_23_1
  article-title: Processing by convertases is not required for glypican‐3‐induced stimulation of hepatocellular carcinoma growth
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M507004200
– volume: 67
  start-page: 57
  issue: 1
  year: 2007
  ident: e_1_2_12_32_1
  article-title: Role for amplification and expression of glypican‐5 in rhabdomyosarcoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1650
– ident: e_1_2_12_52_1
  doi: 10.1016/j.ydbio.2005.03.003
– volume: 127
  start-page: 1565
  issue: 7
  year: 2014
  ident: e_1_2_12_56_1
  article-title: Glypican‐3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling
  publication-title: J Cell Sci
– ident: e_1_2_12_77_1
  doi: 10.1002/hep.24289
– ident: e_1_2_12_136_1
  doi: 10.1073/pnas.1217868110
– ident: e_1_2_12_3_1
  doi: 10.1016/S0140-6736(11)61347-0
– ident: e_1_2_12_135_1
  doi: 10.4161/mabs.20933
– ident: e_1_2_12_141_1
  doi: 10.1007/s00262-012-1366-6
– ident: e_1_2_12_178_1
  doi: 10.1177/1533034615605248
– ident: e_1_2_12_22_1
  doi: 10.3389/fonc.2014.00015
– ident: e_1_2_12_30_1
  doi: 10.1111/jdi.12071
– ident: e_1_2_12_98_1
  doi: 10.1007/s00535-013-0793-2
– volume: 19
  start-page: 778
  issue: 6
  year: 2013
  ident: e_1_2_12_90_1
  article-title: MicroRNA‐1291‐mediated silencing of IRE1 alpha enhances glypican‐3 expression
  publication-title: RNA
  doi: 10.1261/rna.036483.112
– ident: e_1_2_12_88_1
  doi: 10.1002/hep.25994
– ident: e_1_2_12_105_1
  doi: 10.1016/j.acthis.2008.11.025
– ident: e_1_2_12_161_1
  doi: 10.1053/j.gastro.2015.05.055
– ident: e_1_2_12_2_1
  doi: 10.1002/ijc.29210
– ident: e_1_2_12_101_1
  doi: 10.1016/j.jhep.2008.11.014
– ident: e_1_2_12_54_1
  doi: 10.3892/mmr.2014.2600
– ident: e_1_2_12_51_1
  doi: 10.1016/j.ydbio.2009.08.029
– ident: e_1_2_12_91_1
  doi: 10.1111/hepr.12121
– volume: 14
  start-page: 7345
  issue: 12
  year: 2013
  ident: e_1_2_12_107_1
  article-title: Can glypican‐3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2013.14.12.7345
– ident: e_1_2_12_63_1
  doi: 10.1371/journal.pone.0137664
– volume: 7
  start-page: 42150
  issue: 27
  year: 2016
  ident: e_1_2_12_121_1
  article-title: Expression of oncofetal antigen glypican‐3 associates significantly with poor prognosis in HBV‐related hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9892
– ident: e_1_2_12_103_1
  doi: 10.1309/AJCPK1ZC9WNHCCMU
– ident: e_1_2_12_12_1
  doi: 10.1053/j.gastro.2006.09.014
– volume: 64
  start-page: 2418
  issue: 7
  year: 2004
  ident: e_1_2_12_36_1
  article-title: Identification of soluble NH2‐terminal fragment of glypican‐3 as a serological marker for early‐stage hepatocellular carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-03-2191
– ident: e_1_2_12_160_1
  doi: 10.1158/1078-0432.CCR-14-1170
– ident: e_1_2_12_113_1
  doi: 10.1016/j.clinbiochem.2013.12.007
– ident: e_1_2_12_64_1
  doi: 10.1038/nrc2853
– volume: 132
  start-page: 1723
  issue: 11
  year: 2008
  ident: e_1_2_12_164_1
  article-title: Glypican‐3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/132.11.1723
– ident: e_1_2_12_177_1
  doi: 10.1111/j.1872-034X.2010.00624.x
– ident: e_1_2_12_55_1
  doi: 10.1016/j.jhep.2013.07.001
– ident: e_1_2_12_72_1
  doi: 10.1158/0008-5472.CAN-05-0616
– ident: e_1_2_12_7_1
  doi: 10.1016/S0016-5085(03)00689-9
– ident: e_1_2_12_49_1
  doi: 10.1074/jbc.M410090200
– volume: 28
  start-page: 497
  issue: 4
  year: 2011
  ident: e_1_2_12_153_1
  article-title: Inhibition of glypican‐3 expression via RNA interference influences the growth and invasive ability of the MHCC97‐H human hepatocellular carcinoma cell line
  publication-title: Int J Mol Med
– ident: e_1_2_12_175_1
  doi: 10.1016/j.cca.2013.04.026
– ident: e_1_2_12_163_1
  doi: 10.1111/j.1478-3231.2005.01100.x
– ident: e_1_2_12_144_1
  doi: 10.1080/2162402X.2015.1129483
– volume: 13
  start-page: 703
  issue: 3
  year: 2013
  ident: e_1_2_12_11_1
  article-title: Diagnostic value of glypican‐3 in alpha fetoprotein negative hepatocellular carcinoma patients
  publication-title: Afr Health Sci
– ident: e_1_2_12_124_1
  doi: 10.1111/apm.12491
– ident: e_1_2_12_39_1
  doi: 10.3748/wjg.v22.i1.275
– ident: e_1_2_12_19_1
  doi: 10.1038/bjc.2016.183
– ident: e_1_2_12_130_1
  doi: 10.1158/0008-5472.CAN-08-1973
– volume: 40
  start-page: 1356
  issue: 3
  year: 2012
  ident: e_1_2_12_89_1
  article-title: Molecular basis of differential target regulation by miR‐96 and miR‐182: The glypican‐3 as a model
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkr843
– ident: e_1_2_12_156_1
  doi: 10.1002/jcb.24404
– volume: 8
  start-page: 505
  issue: 9
  year: 2012
  ident: e_1_2_12_29_1
  article-title: Obesity: Glypican‐4: Role in insulin signalling
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2012.133
– ident: e_1_2_12_35_1
  doi: 10.3892/mco.2015.486
– ident: e_1_2_12_68_1
  doi: 10.4161/cbt.8.24.9985
– ident: e_1_2_12_108_1
  doi: 10.1007/s11033-013-2829-3
– volume: 1
  start-page: 14
  issue: 1
  year: 2011
  ident: e_1_2_12_25_1
  article-title: The role of glypican‐3 in regulating Wnt in hepatocellular carcinomas
  publication-title: Cancer Rep
– ident: e_1_2_12_27_1
  doi: 10.1002/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I
– volume: 18
  start-page: 2408
  issue: 19
  year: 2012
  ident: e_1_2_12_126_1
  article-title: Glypican‐3 expression and its relationship with recurrence of HCC after liver transplantation
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v18.i19.2408
– ident: e_1_2_12_41_1
  doi: 10.1136/gut.48.4.558
– volume: 163
  start-page: 625
  issue: 3
  year: 2003
  ident: e_1_2_12_44_1
  article-title: Processing by proprotein convertases is required for glypican‐3 modulation of cell survival, Wnt signaling, and gastrulation movements
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200302152
– volume: 116
  start-page: 1582
  issue: 6
  year: 2006
  ident: e_1_2_12_61_1
  article-title: Met‐regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
  publication-title: J Clin Investig
  doi: 10.1172/JCI27236
SSID ssj0011513
Score 2.6390512
SecondaryResourceType review_article
Snippet Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are...
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 741
SubjectTerms Biomarkers, Tumor - metabolism
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Disease Progression
Glypicans - blood
Glypicans - chemistry
Glypicans - metabolism
glypican‐3
hepatocellular carcinoma
Humans
Liver cancer
Liver Neoplasms - blood
Liver Neoplasms - diagnosis
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Medical imaging
Molecular Targeted Therapy
Title Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmed.21455
https://www.ncbi.nlm.nih.gov/pubmed/28621802
https://www.proquest.com/docview/2001376460
https://www.proquest.com/docview/1910794658
Volume 38
WOSCitedRecordID wos000425027400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1098-1128
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0011513
  issn: 0198-6325
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSyQxEC503MNefO3D8UVWFtmDs6aTfqT1JOqsB1eGZRbm1qTTaRSkR6ZHYW7-BH-jv8SqTk8PooLgoaEhFRIqlapKUvUVwE8dycxGhKctDV3d6Az1oPQ6RkXWV7lCE2SqYhPRxYUaDOLeHBxOc2EcPkRz4UY7o9LXtMF1Wu7PQEPRWPyuYLbnYUGg3AYtWDj51_1_3jwioDGTLltadUIpgimwEBf7Tefn5uiFj_ncZa1sTnfpQ7NdhsXa1WRHTjZWYM4Wq7Dbc1jVkz3Wn6VelXtsl_VmKNaTLzD4cz25IR35eP8gD9gRw1mjTKClY5SyT1E9I4YeL7tEgzYe0gMARbQyQ8WJCiRgmYviuyqZLjLWRLR_hX73tH981qnLMHSMT5UcI5nLjIdaitgG3E9VqnhguIq15iLXRiqdCqmVzaW1lAkrpYhiq_I4zj0r5DdoFcPCrgHztQ6xgWdZnvrKj9MMP18HgQ6Fp3OvDb-mi5GYGqKcKmVcJw5cWSTIxqRiYxt2GtIbh8vxGtHmdEWTemuWVHfTQ63qh7wNP5pmZCAxShd2eFsmeIjlhLwfqDZ8d5LQjCLwDEiweTjZasHfHj75e3pS_ay_n3QDPqNLplyU2ya0xqNbuwWfzN34qhxtw3w0UNu1nD8BYfj_0Q
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9swED-6drC9tN2frlnbTRuj7KFZZUm25bGXsjZtWRrCyCBvRpZlVihOidNB3voR-hn3SXZnOQ5lGwz2YDDohMTpdHeS7n4H8M7EMncx4WlLS1c3Jkc9KIOu1bFTutBogmxdbCIeDPR4nAxX4NMiF8bjQ7QXbrQzan1NG5wupA-XqKFoLT7UONsPYE2hGKF8rx1_7X3rt68IaM2kT5fW3UiKcIEsxMVh2_m-PfrNybzvs9ZGp7fxf9PdhPXG2WRHXjqewIorn8L-0KNVzw_YaJl8VR2wfTZc4ljPn8H49Gp-TVry5-2d_MiOGE4bpQJtHaOkfYrrmTL0edl3NGmzCT0BUEwrs1SeqEQClvs4vsuKmTJnbUz7cxj1Tkafz7pNIYauVVTLMZaFzHlkpEhcyFWmM81Dy3ViDBeFsVKbTEijXSGdo1xYKUWcOF0kSRE4IbdgtZyUbhuYMibCBp7nRaa0SrIcP2XC0EQiMEXQgfeL1UhtA1JOtTKuUg-vLFJkY1qzsQNvW9Jrj8zxJ6LdxZKmzeasqPJmgHpVRbwDb9pmZCAxypRuclOleIzlhL0f6g688KLQjiLwFEjAeTjZesX_Pnx6cXJc_7z8d9LX8OhsdNFP--eDLzvwGB007WPedmF1Nr1xe_DQ_phdVtNXjbj_AqYtAug
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fixMxEB_Onogv_j-tnhpFDh-uXjbJ7mbFl8NeVTxLkQp9W7L5gwfHtnR7Qt_8CH5GP4kzu9sthwqCDwsLmZAwmcxMkpnfALwwqXQ-JTxtaenqxjjUgzIaWJ16pYNGE2TrYhPpeKxns2yyA282uTANPkR34UY7o9bXtMH9woWjLWooWotXNc72FdhVVESmB7vDz6Mvp90rAloz2aRL60EiRbxBFuLiqOt82R795mRe9llrozO6-X_TvQU3WmeTHTfScRt2fHkHDiYNWvX6kE23yVfVITtgky2O9fouzN6drxekJX9-_yFfs2OG00apQFvHKGmf4nqWDH1e9hVN2mpOTwAU08oslScqkYC5Jo7vrGKmdKyLab8H09HJ9O37QVuIYWAV1XJMZZCOJ0aKzMdcFbrQPLZcZ8ZwEYyV2hRCGu2D9J5yYaUUaeZ1yLIQeSH3oFfOS_8AmDImwQbuXCiUVlnh8FMmjk0iIhOiPrzcrEZuW5ByqpVxnjfwyiJHNuY1G_vwvCNdNMgcfyLa3yxp3m7OiipvRqhXVcL78KxrRgYSo0zp5xdVjsdYTtj7se7D_UYUulEEngIJOA8nW6_434fPP50M65-H_076FK5NhqP89MP44yO4jv6ZbkLe9qG3Wl74x3DVfludVcsnrbT_Ai2NAmM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glypican-3%3A+A+promising+biomarker+for+hepatocellular+carcinoma+diagnosis+and+treatment&rft.jtitle=Medicinal+research+reviews&rft.au=Zhou%2C+Fubo&rft.au=Shang%2C+Wenting&rft.au=Yu%2C+Xiaoling&rft.au=Tian%2C+Jie&rft.date=2018-03-01&rft.eissn=1098-1128&rft.volume=38&rft.issue=2&rft.spage=741&rft_id=info:doi/10.1002%2Fmed.21455&rft_id=info%3Apmid%2F28621802&rft.externalDocID=28621802
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0198-6325&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0198-6325&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0198-6325&client=summon